// App-Quantinova.ai

DOP008 : Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry

Researchers

Presenter

  • D Turner

Principal Investigators

  • H Winter

  • R Baldassano

  • M Dubinsky

  • W Faubion

  • J Hyams

  • S Kugathasan

  • J Rosh

  • J Escher

  • A Griffiths

  • J Kierkus

  • R Russell

  • G Heap

  • D Arikan

  • V Kuehnl

  • J Petersson

  • A Robinson

  • F Ruemmele

Medical Centers

  • Institute of Paediatric Gastroenterology, Shaare Zedek Medical Centre, The Hebrew University of Jerusalem, Jerusalem, Israel

  • Dr. von Hauner Children’s Hospital, University Medical Center, LMU Munich, Munich, Germany

  • Department of Pathology, Massachusetts General Hospital, Boston, MA

  • Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA

  • Department of Pediatrics, Division of Gastroenterology, Mount Sinai Medical Center, New York, USA

  • Mayo Clinic, Gastroenterology and Hepatology, Rochester, MN

  • Division of Digestive Diseases, Connecticut Children’s Medical Center, Hartford, USA

  • Emory University School of Medicine and Children?s Healthcare of Atlanta, Atlanta, GA

  • Division of Gastroenterology and Nutrition, Boston Childrens Hospital, Boston, MA

  • Erasmus University Medical Center-Sophia Childrens Hospital, Rotterdam, Netherlands

  • Department of Pediatrics, The Hospital for Sick Children and the University of Toronto, Toronto, ON, Canada

  • Gastroenterology, Hepatology, Eating Disorders and Pediatrics, Childrens Memorial Health Institute, Warsaw, Poland

  • Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom

  • AbbVie, Inc., North Chicago, IL

  • AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • AbbVie, Inc., North Chicago, IL

  • Paediatric Gastroenterology, Hôpital Necker Enfants Malades, APHP, University Paris Descartes Sorbonne Paris Cité, Paris, France

Locations

  • Israel

  • Germany

  • United States

  • Netherlands

  • Canada

  • Poland

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Allmercap

  • Oraprine

  • Methotrexate

  • Adalimumab

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved